The content on this site is intended for healthcare professionals only
Dr Luis Raez speaks to ecancer about the latest updates from the WCLC and ESMO 2023.
He speaks about the ALINA, TRIDENT-1, MARIPOSA-1, MARIPOSA-2, PAPILLON, CHECKMATE 77T and KEYNOTE-671 trials.
He concludes by talking about the future of lung cancer treatment.
ASCO GU 2026: Updates in metastatic prostate cancer
ASCO GU 2026: Updates in localised prostate cancer
Key insights from lung cancer research at ASCO 2025
ELCC 2025: Latest in EGFR positive NSCLC
Made to measure: Choosing the optimal regimen in transplant-eligible NDMM
ESMO and WCLC: Latest developments in EGFR mutated NSCLC
Isa-KRd quad regimen in NDMM: MIDAS and CONCEPT studies
Comment: Trial updates from GALAXIES Lung-201 and RELATIVITY-104 in NSCLC
ESMO 2024: Best practice in HRRm testing in patients with metastatic prostate cancer
